This is the latest edition of the IBTA e-news bulletin. Find out more about us at
View this email in your browser

Forward this to a friend
Share this:
share on Twitter
Like The IBTA e-News November 2014 on Facebook
Google Plus One Button

IBTA e-news

The monthly bulletin for our
international brain tumour community

November 2014

Important news

Novocure Announces the EF-14 Phase III Clinical Trial of Tumor Treating Fields in Patients with Newly Diagnosed Glioblastoma has been Terminated at the Interim Analysis due to Early Success

"Data presented as a late-breaking abstract at the Society for Neuro- Oncology 2014 Annual Meeting in Miami demonstrated the study met its primary endpoint of progression-free survival and secondary endpoint of overall survival in an interim analysis. The EF-14 trial Independent Data Monitoring Committee recommended terminating the trial early and allowing all control patients to receive Tumor Treating Fields..." Read more (company press release). Novocure have also announced that the NovoTTF™-100A will now be known as Optune. 

Rindopepimut immunotherapy prolongs survival in recurrent glioblastoma

Celldex Therapeutics, Inc. has that announced an interim update from the Phase 2 ReACT study of rindopepimut in EGFRvIII-positive glioblastoma (GBM) "demonstrates clear signs of clinical activity in patients with recurrent glioblastoma, including groups both naïve and refractory to bevacizumab (Avastin®). The data were presented in a platform presentation by David A. Reardon, M.D., Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Center and Associate Professor of Medicine, Harvard Medical School, and the lead investigator of the ReACT study...[at] the 19th Annual Meeting of the Society for Neuro-Oncology (SNO)..." Read more (company press release).

All clinical reports to be made public, European Medicines Agency announces

From 1 January 2015, the public will have online access to all clinical reports used by the European Medicines Agency (EMA) in their decision making process for approving new drugs. Guido Rasi, EMA Executive Director says of this that “this policy sets a new standard for transparency in [...] research and development. This unprecedented level of access to clinical reports will benefit patients, healthcare professionals, academia and industry.” Read more.

Dr Mark Gilbert appointed Chief of the Neuro-Oncology Branch at the US National Cancer Institute

The IBTA would like to warmly congratulate Dr Mark Gilbert who has been appointed Senior Investigator and Chief of the Neuro-Oncology Branch (NOB) in the Center for Cancer Research (CCR), National Cancer Institute (NCI). The branch holds key responsibilities in developing new brain tumour therapies. Read more.

Society for Neuro-Oncology Latin America (SNOLA) officially launched

After the culmination of many months of hard work, the Society for Neuro-Oncology Latin America (SNOLA) was officially launched on 1 November 2014 which coincided with International Brain Tumour Awareness Week. The organisation aims to advance the treatment and care for brain tumour patients across Latin America. Read more (The SNOLA President’s words for the IBTA).

As it happened: Society for Neuro-Oncology (SNO) Meeting abstracts online

The abstracts for the 19th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) which took place from 13 - 16 November in Miami, Florida, can be viewed online here (full articles require payment/subscription). Watch out for the IBTA’s SNO report in the December issue of the IBTA e-news.

Research roundup

Stem cells that kill brain tumours created

In research published in Stem Cells, Harvard University researchers genetically engineered animal stem cells that will produce tumour-killing toxins continuously. Mice experiments showed that implanting these cells into the brains of mice after glioblastoma resection was highly effective at preventing tumour regrowth. Read more.

Brain tumour risk and mobile phone use

Published in the journal Pathophysiology, a Swedish-based analysis of pooled case-control studies found that people with gliomas reported greater mobile phone use than those without. The significance of these findings has been questioned. Read more (discussion of results).

Different brain tumour types may have the same origin

Historically, it has been thought different glioma types arise from different cell types. Research published in The Journal of Neuroscience challenges this; both astrocytoma and oligodendroglioma tumour types can develop from the same cell origin. Read more.  

Virus therapy may get a boost with chemotherapy

Experimental oncolytic virus therapy for malignant gliomas might be made more effective if given alongside the common chemotherapeutic agent cyclophosphamide according to animal based research published in Cancer Research. Read more.

Approval granted for antineoplaston clinical trials

The US Food and Drug Administration (FDA) have, for the first time, granted approval for the phase III clinical testing of Dr Stanislaw Burzynski’s antineoplaston therapy. The trial is for paediatric brain tumour patients with diffuse intrinsic pontine glioma. Read here for a discussion of the nature of this very controversial type of treatment. Read more (press release).

Research suggests delaying radiation therapy to improve survival with newly diagnosed glioblastoma

In research presented at the Congress of Neurological Surgeons 2014 Annual Meeting, data shows that patients with newly diagnosed glioblastoma have improved outcomes when radiation therapy is delayed by 30 - 35 days after initial surgery. Read more.

IBTA news

The IBTA International Brain Tumour Awareness Week (26 Oct - 1 Nov 2014)

We thank all of you for your wonderful efforts in helping to increase awareness about brain tumours around the world. Catch up with some of the 2014 Awareness Week activities by visiting our twitter stream @theIBTA and seeing all the tweets with the hashtag #IBTAWeek. Also like our Facebook Page to find photos and stories from the week.

IBTA Chair Kathy Oliver speaks at 1st Bulgarian European Brain Council (EBC) Symposium

Held in Sofia, Bulgaria, on 7 November 2014, this inaugural symposium presented the challenges and opportunities that Bulgarian neurology, neurosurgery, psychiatry, patients and business have to face in this period of economic crisis.  Kathy Oliver presented on how the IBTA is working to raise awareness of brain tumours around the world and described the challenges faced on this journey by brain tumour patients and caregivers. Read more.

News from other organisations

Brain Tumour Society Singapore roars into life on 1 November

A new non-profit organisation was launched in Singapore on Saturday November 1st during International Brain Tumour Awareness Week. The Brain Tumour Society Singapore (BTSS) is made up of medical professionals, patients, survivors and caregivers. The President of the new group is Ms Melissa Lim, herself a brain tumour survivor.  Read more.

Carol Kruchko, president of US brain tumor registry shares her inspirational story

When her 3 year old son died of a brain tumour, Carol Kruchko found a way to honour his memory and help others. In 1992, she founded what is now the Central Brain Tumor Registry of the United States (CBTRUS) - the largest population-based database of the incidence of all primary brain and central nervous system tumours in the US. Read more.

Upcoming conferences

Keep up to date with future scientific conferences on the IBTA website conferences page here. If you are aware of a brain tumour-relevant conference - including any patient conferences - that we have not yet listed on the IBTA website then please let us know.

Here is a selection of forthcoming conferences. For the full listing, please see the IBTA website.

26th EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
18-21 November 2014
Barcelona, Spain
I Tumori Rari dell'adulto
21-22 November 2014
Bologna, Italy

STOP PRESS - British Neuro-Oncology Society (BNOS) Annual Meeting 2015

It has been announced that the BNOS 2015 meeting will be held on 1 - 3 July 2015 at East Midlands Conference Centre, Nottingham University, UK. 
Abstract submission is in February/March and registration opens April 2015. Read more

And finally...

'Luckiest' accident ever?

A cyclist says he feels like “the luckiest person in the world” to have been hit by a black cab — because it led to the discovery of a brain tumour. Paul Bartlett, 37, from East Dulwich, [London, UK] was diagnosed by chance after being invited to take part in a research project following his stay in hospital. Read more.

IBTA Website
IBTA Website


Who we are

The International Brain Tumour Alliance was established in 2005. It is a network of support, advocacy and information groups representing brain tumour patients and carers in different countries and also includes researchers, scientists, clinicians and allied health professionals who work in the field of brain tumours.
For more information, please visit  


Tell us what you think!

We love to hear from you if you have any news that you would like to share with the IBTA community. Just send us an email:
We will do our best to relay as much information as possible to our subscribers via this monthly newsletter and our website. The selection of e-News entries is at the sole discretion of the editors.
Copyright © 2014 The International Brain Tumour Alliance, All rights reserved.


The International Brain Tumour Alliance (IBTA) makes every effort to be accurate regarding the information contained in this e-newsletter. However, the IBTA accepts no liability for any inaccuracies or omissions herein nor can it accept liability for any loss or damage resulting from any inaccuracy in this information or third party information such as information on websites to which we link. The information contained on this e-newsletter is for educational purposes only and should in no way be taken as a substitute for medical care nor is the information on this website meant to constitute medical advice or professional services. For medical care and advice, please contact your doctor.

Other websites linked from the IBTA e-newsletters are not under the control of the IBTA. Therefore we take no responsibility for their content. The IBTA has provided these links as a convenience to you and can in no way verify the information, quality, safety or suitability of linked websites.

Any company sponsorship of the IBTA's projects does not imply the IBTA's endorsement of any particular form or forms of therapy, treatment regimen or behaviour. (For further details of our sponsors, please see our Sponsorship Policy).

Some of the views and opinions in the materials included in this e-newsletter may not necessarily be those of the International Brain Tumour Alliance.

unsubscribe from this list    update subscription preferences 
Email Marketing Powered by Mailchimp